Continuous treatment with abemaciclib leads to sustained and efficient inhibition of breast cancer cell proliferation

Abemaciclib is an oral, selective cyclin-dependent kinase 4 & 6 inhibitor (CDK4 & 6i), approved for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) as monotherapy for endocrine refractory disease, and with endocrine ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Torres-Guzmán, Raquel, Ganado, Maria Patricia, Mur, Cecilia, Marugan, Carlos, Baquero, Carmen, Yang, Yanzhu, Zeng, Yi, Bian, Huimin, Du, Jian, de Dios, Alfonso, Puig, Oscar, Lallena, María José
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2022
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9255995/
https://www.ncbi.nlm.nih.gov/pubmed/35813283
http://dx.doi.org/10.18632/oncotarget.28249

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9255995/
https://www.ncbi.nlm.nih.gov/pubmed/35813283
http://dx.doi.org/10.18632/oncotarget.28249

Ejemplares similares